S&P 500 Futures
(-0.08%) 5 304.25 points
Dow J Futures
(-0.09%) 40 140 points
Nasdaq Futures
(-0.05%) 18 465 points
Oil
(-0.07%) $83.11
Gas
(-0.62%) $1.752
Gold
(0.73%) $2 254.80
Silver
(0.74%) $25.10
Platinum
(0.21%) $923.00
USD/EUR
(0.16%) $0.928
USD/NOK
(0.14%) $10.86
USD/GBP
(-0.03%) $0.792
USD/RUB
(-0.11%) $92.47

Realtime updates for Reata Pharmaceuticals Inc [RETA]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Last Updated25 Sep 2023 @ 16:00

0.02% $ 172.36

Live Chart Being Loaded With Signals

Commentary (25 Sep 2023 @ 16:00):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302
Profile picture for Reata Pharmaceuticals Inc

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases...

Stats
Today's Volume 1.91M
Average Volume 954 093
Market Cap 6.57B
EPS $0 ( 2024-02-22 )
Next earnings date ( $0 ) 2024-05-08
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -66.29
ATR14 $1.830 (1.06%)
Insider Trading
Date Person Action Amount type
2023-09-26 Desai Antal Rohit Sell 134 Class A common stock
2023-09-26 Desai Antal Rohit Sell 993 929 Class B common stock
2023-09-26 Mcgaughy R Kent Jr Sell 280 Class A common stock
2023-09-26 Mcgaughy R Kent Jr Sell 278 309 Class B common stock
2023-09-26 Mcgaughy R Kent Jr Sell 699 Stock Option (right to buy)
INSIDER POWER
-100.00
Last 100 transactions
Buy: 0 | Sell: 4 695 639

Volume Correlation

Long: 0.09 (neutral)
Short: -0.26 (neutral)
Signal:(84.692) Neutral

Reata Pharmaceuticals Inc Correlation

10 Most Positive Correlations
CREX0.957
MYRG0.875
ALLR0.869
MSSA0.849
SGEN0.847
NETE0.835
PLYA0.832
MHUA0.831
USAP0.83
SGTX0.825
10 Most Negative Correlations
RMGBU-0.875
ENVI-0.851
EJFA-0.838
ONEM-0.837
ESSA-0.837
SVOK-0.824
SAII-0.819
FNCB-0.818
BSBK-0.816
PAIC-0.814

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Reata Pharmaceuticals Inc Correlation - Currency/Commodity

The country flag -0.86
( strong negative )
The country flag -0.64
( weak negative )
The country flag 0.50
( weak )
The country flag -0.78
( moderate negative )
The country flag -0.17
( neutral )
The country flag 0.89
( strong )

Reata Pharmaceuticals Inc Financials

Annual 2022
Revenue: $2.22M
Gross Profit: $2.22M (100.00 %)
EPS: $-8.59
Q2 2023
Revenue: $22.75M
Gross Profit: $21.90M (96.28 %)
EPS: $5.12
Q1 2023
Revenue: $195 000
Gross Profit: $195 000 (100.00 %)
EPS: $-3.00
Q4 2022
Revenue: $914 000
Gross Profit: $914 000 (100.00 %)
EPS: $-2.35

Financial Reports:

No articles found.

Reata Pharmaceuticals Inc

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators